Clinical Trials Arena is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Rozlytrek (entrectinib) for the Treatment of Solid Cancerous Tumours

Drug Name

Rozlytrek (entrectinib)

Developer

Roche and Chugai Pharmaceutical

Therapy Class

Kinase inhibitor

Product Description

CNS-active tyrosine kinase inhibitor

Current Indication

Solid tumours

Market Sector

Oncology

Development Status

Approved in Japan
Expand
Close
Close
Close

Go Top